Member Exclusive

Autologous cell therapies: challenges in US FDA regulation

Read this Opinion, published in Regenerative Medicine, to understand why after 30 years of laboratory and clinical efforts fueled by countless billions in public and private funding, cell-based therapies have not made a greater impact.

Go to the profile of Regenerative Medicine
May 30, 2017

Please sign in or register for FREE

No comments yet.